Add BrightSurf on Google Email

Mount Sinai scientists validate a link between autoimmunity in a subset of people with long COVID

Researchers at Mount Sinai have found that autoimmunity is responsible for the symptoms of long COVID in a subset of people. The study suggests that therapies already validated for managing autoimmunity, such as IVIG and FcRn inhibitors, could be effective in reducing symptom burden.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalCell·TypeRandomized controlled/clinical trial·DateMay 28, 2026

UCLA studies point to new way to fight potentially deadly Valley Fever

UCLA researchers have found that patients with severe Valley Fever had abnormal immune responses, including overactive or underactive T cells. The team discovered two underlying immune programs that contribute to life-threatening disseminated Valley Fever and developed a new treatment approach using immunomodulation.

SourceUniversity of California - Los Angeles Health Sciences·JournalJCI Insight·TypeExperimental study·DateMay 26, 2026

CODA supports international collaboration between Stellenbosch University and Massachusetts Institute of Technology to advance microvascular research in complex chronic disorders

The Complex Disorders Alliance (CODA) is funding research on microvascular dysfunction and immune-mediated clotting processes in complex chronic disorders. Professor Resia Pretorius of Stellenbosch University and Dr. Mikki Tal of MIT are collaborating to expand understanding of these conditions.

The cost of delaying childhood vaccination

A new study from Cornell University found that delaying the first dose of hepatitis B vaccine after birth leads to increased infections and higher healthcare costs. The longer the delay, the more severe the consequences for newborns, who are at high risk of developing chronic infections and premature death.

SourceCornell University·JournalJAMA Pediatrics·DateApr 27, 2026

Characteristics of CD4+T-cell reduction and pulmonary infections in critically ill immunocompromised patients

A retrospective study of 40 immunocompromised ICU patients found associations between low CD4+T-cell counts and specific lung pathogens. Patients with severe CD4 depletion had higher proportions of fungal infections, while moderate immunosuppression was linked to Streptococcus pneumoniae.

SourceJournal of Intensive Medicine·JournalJournal of Intensive Medicine·TypeObservational study·DateApr 2, 2026

Gut microbiota differs in children with rare food allergy

Children with rare food allergy FPIES exhibit atypical gut microbiota compared to healthy peers, according to a new Umeå University study. The analysis of stool samples revealed differences in bacterial composition associated with FPIES, which may contribute to the development of more individualized strategies for diagnosis and treatment.

SourceUmea University·JournalJournal of Allergy and Clinical Immunology·TypeExperimental study·DateApr 2, 2026

Bringing diabetes treatment into focus

Researchers at Kyoto University developed a PET tracer to quantify beta cell mass in type 1 diabetes patients, revealing lower uptake in those with the disease. This measurement was inversely related to hemoglobin A1c and total daily insulin dose, suggesting its potential as a noninvasive readout of residual beta cell mass.

SourceKyoto University·JournalDiabetes·TypeRandomized controlled/clinical trial·DateMar 12, 2026

Why does the body deem some foods safe and others unsafe?

Researchers have identified three new proteins, called epitopes, that help the body determine 'safe' foods, aiding in food tolerance and allergy understanding. The epitopes were found in seed proteins from corn, wheat, and soybean, and interact with regulatory T cells to inform tolerance-or-rejection decisions.

SourceSalk Institute·JournalScience Immunology·DateMar 6, 2026

Using the vagus nerve to treat disease: Review maps today’s science, points to tomorrow’s therapies

A comprehensive review synthesizes the science behind vagus nerve modulation therapies, which use controlled signals to influence brain circuits and inflammation. The authors identify key mechanisms and propose next-generation treatments tailored to individual patients and conditions.

SourceUniversity of California - San Diego·JournalComprehensive Physiology·TypeSystematic review·DateMar 5, 2026

Exposing a hidden anchor for HIV replication

Scientists at the University of Delaware discovered a previously unknown structural role for the HIV integrase protein, which forms gluey filaments that anchor the RNA genome to the capsid. This discovery provides a promising new target for drug development and could lead to the development of next-generation inhibitors.

SourceUniversity of Delaware·JournalNature·DateFeb 18, 2026

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

Insilico Medicine and CMS announce multiple collaborations on AI-empowered drug discovery in central nervous system and autoimmune diseases. The partnerships aim to accelerate research, development, and translation of high-potential innovative therapies, leveraging complementary strengths across the entire value chain.

Inflammation and autoimmune-like dysfunction may play a role in heart failure

A recent study from Penn State College of Medicine researchers found that helper T cells, typically involved in fighting infections, become overly activated in failing human hearts, causing damage. The activation of these T cells highlights the impact of inflammation and immune dysfunction in heart failure.

SourcePenn State·JournalJournal of Molecular and Cellular Cardiology·TypeObservational study·DateJan 27, 2026

Genomic maps untangle the complex roots of disease

Researchers develop comprehensive method to connect diseases with underlying genetic machinery, revealing intricate gene networks that influence complex traits. The new technique provides actionable insights into how specific genes affect cell functions, shedding light on biological mechanisms and potential therapeutic targets.

SourceGladstone Institutes·JournalNature·DateDec 10, 2025

Breakthrough pediatric kidney therapy emerges from U. Iowa research

Researchers at the University of Iowa Health Care have developed a new class of medication, pegcetacoplan, which directly targets the root cause of C3 glomerulopathy, a rare and severe kidney disease. The treatment has shown significant results, with up to 67% of children achieving complete remission and stabilization of kidney function.

SourceUniversity of Iowa Health Care·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 3, 2025

Old drug, new use: How a cheap, century-old drug can improve life with type 1 diabetes

A Garvan-led clinical trial has found that using metformin, a common type 2 diabetes medication, reduces the amount of insulin needed to maintain blood sugar levels in type 1 diabetes. The study suggests that metformin may serve as an affordable treatment option for people with type 1 diabetes.

SourceGarvan Institute of Medical Research·JournalNature Communications·TypeRandomized controlled/clinical trial·DateNov 24, 2025

Autoimmune hepatitis associated with other autoimmune diseases

Autoimmune hepatitis is often associated with other autoimmune conditions, including thyroid disease, type 1 diabetes, inflammatory bowel disease, and rheumatologic disorders. The study highlights the need for precise diagnostic criteria and interdisciplinary management strategies to optimize outcomes in patients with multi-organ autoi...

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateNov 10, 2025

Researchers find potential link between chronic pain, immune condition

A study led by Julie Pilitsis, MD, PhD, found a possible connection between chronic pain and eosinophilia, a white blood cell condition, in patients undergoing spinal cord stimulation or implanted pain medicine pumps. The study suggests that eosinophilia may be an immune biomarker for chronic pain.

SourceUniversity of Arizona Health Sciences·JournalNeuromodulation Technology at the Neural Interface·TypeData/statistical analysis·DateOct 9, 2025